Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Orencia Pharmacovigilance Plan Could Become Industry Standard

Executive Summary

Bristol-Myers Squibb's proposed pharmacovigilance program for its rheumatoid arthritis therapy Orencia (abatacept) is indicative of a trend toward enhanced safety monitoring, Arthritis Advisory Committee industry representative Roger Porter (formerly with Wyeth) said Sept. 8

You may also be interested in...



Orencia Marketing Likely To Focus On Broader Mechanism Of Action

Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS046299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel